The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Validation of adverse risk subgroups in patients with AML undergoing alloSCT
Carlos Jimenez-Vicente, MD, Hospital Clinic Barcelona, Barcelona, Spain, comments on a study evaluating the European LeukemiaNet (ELN) 2022 risk classification of patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (alloSCT). This study validated previous findings, indicating two distinct subgroups within the adverse risk group. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So what we performed is that we had already evaluated the prognostic value of the European Leukemia 2022 risk classification in allografted AML patients. And when we performed a single-centre study that was published this year, what we observed initially is that the adverse risk group could be divided in two different groups with really different outcomes. But this study lacked loads of patients and MRD assessment was also lacking...
So what we performed is that we had already evaluated the prognostic value of the European Leukemia 2022 risk classification in allografted AML patients. And when we performed a single-centre study that was published this year, what we observed initially is that the adverse risk group could be divided in two different groups with really different outcomes. But this study lacked loads of patients and MRD assessment was also lacking. So we performed a validation in 16 centers within Spanish institutions. We had a total number of 651 patients and with these numbers we were able to validate the fact that the adverse risk group can be divided in two different subgroups with really different outcomes in allografted AML patients. Also what we observed is patients located in the adverse risks that do not have really adverse abnormalities, have similarities to the intermediate risk group and this might also offer new therapeutic strategies for those patients that have the worst outcome.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AbbVie: Speakers Bureau; AbbVie: Other: Travel Grants.
